SNDX Syndax Pharmaceuticals Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1395937 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY159.7%
TTM net income YoY32.8%
TTM EPS YoY34.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-61.7%
Net margin-72.3%
FCF margin—
EBITDA margin-55.5%
Returns
ROE-426.4%
ROA-33.7%
ROIC (approx.)—
Asset turnover0.47x
Leverage & solvency
Liabilities / assets102.5%
Debt / equity—
Current ratio4.69x
Interest coverage-44,660.00x
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $172.35M | $23.68M | $0 | $0 | $139.71M |
| R&D expense | $258.78M | $241.65M | $163.03M | $118.50M | $88.25M |
| SG&A expense | $179.68M | $120.88M | $66.92M | $33.26M | $25.24M |
| Operating income | -$273.08M | -$339.67M | -$229.95M | -$151.76M | $26.22M |
| Interest expense | $6,000 | -$1,000 | $208,000 | $3.14M | $1.90M |
| Income tax | $433,000 | — | — | — | $0 |
| Net income | -$285.42M | -$318.76M | -$209.36M | -$149.34M | $24.93M |
| EBITDA | -$267.08M | -$331.67M | -$217.95M | -$118.76M | $69.22M |
| EPS (basic) | -3.29 | -3.72 | -2.98 | -2.46 | 0.48 |
| EPS (diluted) | -3.29 | -3.72 | -2.98 | -2.46 | 0.46 |
| Weighted avg. shares (diluted) | 86.63M | 85.62M | 70.37M | 60.76M | 53.62M |
| Balance sheet | |||||
| Cash & equivalents | $134.93M | $154.08M | $295.39M | $74.36M | $221.97M |
| Short-term investments | $259.14M | $418.80M | $275.30M | $401.45M | $217.97M |
| Receivables | $38.00M | $7.60M | $0 | — | — |
| Inventory | $32.75M | $366,000 | $0 | — | — |
| Current assets | $528.08M | $603.06M | $580.88M | $489.79M | $448.40M |
| PP&E, net | $181,000 | $0 | $8,000 | $20,000 | $278,000 |
| Total assets | $529.71M | $724.82M | $612.88M | $497.24M | $449.66M |
| Current liabilities | $120.12M | $103.55M | $58.10M | $29.07M | $20.68M |
| Short-term debt | $343.91M | $343.68M | $0 | — | — |
| Total liabilities | $465.08M | $436.69M | $58.68M | $29.79M | $41.29M |
| Shareholders' equity | $64.63M | $288.12M | $554.20M | $467.45M | $408.37M |
| Shares outstanding | 87.41M | 85.69M | 84.83M | 68.11M | 54.98M |
| Cash flow statement | |||||
| Operating cash flow | -$322.98M | -$274.90M | -$160.60M | -$133.68M | $29.13M |
| Capital expenditure | $187,000 | $0 | $0 | $0 | $129,000 |
| Free cash flow | -$323.17M | -$274.90M | -$160.60M | -$133.68M | $29.00M |
| Investing cash flow | $290.04M | -$219.78M | $117.61M | -$186.19M | -$40.87M |
| Financing cash flow | $13.68M | $353.37M | $264.13M | $172.25M | $118.46M |
| Depreciation & amortization | $6.00M | $8.00M | $12.00M | $33.00M | $43.00M |
| Stock-based compensation | $47.50M | $43.03M | $30.95M | $16.02M | $13.32M |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.